SE168308C1 - - Google Patents
Info
- Publication number
- SE168308C1 SE168308C1 SE168308DA SE168308C1 SE 168308 C1 SE168308 C1 SE 168308C1 SE 168308D A SE168308D A SE 168308DA SE 168308 C1 SE168308 C1 SE 168308C1
- Authority
- SE
- Sweden
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE168308T |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE168308C1 true SE168308C1 (de) |
Family
ID=41958801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE168308D SE168308C1 (de) |
Country Status (1)
| Country | Link |
|---|---|
| SE (1) | SE168308C1 (de) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004017964A1 (en) | 2002-08-19 | 2004-03-04 | Pfizer Products Inc. | Combination therapy for hyperproliferative diseases |
| WO2007062314A2 (en) | 2005-11-23 | 2007-05-31 | Bristol-Myers Squibb Company | Heterocyclic cetp inhibitors |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| EP2392567A1 (de) | 2005-10-21 | 2011-12-07 | Bristol-Myers Squibb Company | Benzothiazinderivate und ihre verwendung als lxr-modulatoren |
| WO2014029841A1 (en) | 2012-08-23 | 2014-02-27 | Cardiolynx Ag | Extended release compositions of an aminoalkyl nitrate |
| WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| WO2016135263A1 (en) | 2015-02-27 | 2016-09-01 | Armin Scherhag | No donors for the treatment of stress-induced pulmonary haemorrhage in animals |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
-
0
- SE SE168308D patent/SE168308C1/xx unknown
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004017964A1 (en) | 2002-08-19 | 2004-03-04 | Pfizer Products Inc. | Combination therapy for hyperproliferative diseases |
| EP2392567A1 (de) | 2005-10-21 | 2011-12-07 | Bristol-Myers Squibb Company | Benzothiazinderivate und ihre verwendung als lxr-modulatoren |
| WO2007062314A2 (en) | 2005-11-23 | 2007-05-31 | Bristol-Myers Squibb Company | Heterocyclic cetp inhibitors |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| WO2014029841A1 (en) | 2012-08-23 | 2014-02-27 | Cardiolynx Ag | Extended release compositions of an aminoalkyl nitrate |
| WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| WO2016135263A1 (en) | 2015-02-27 | 2016-09-01 | Armin Scherhag | No donors for the treatment of stress-induced pulmonary haemorrhage in animals |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| EP4470609A2 (de) | 2019-01-18 | 2024-12-04 | Astrazeneca AB | Pcsk9-inhibitoren und verfahren zur verwendung davon |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020209215B2 (en) | PCSK9 inhibitors and methods of use thereof | |
| EP1545519B1 (de) | Kombinationstherapie gegen hyperproliferative erkrankungen | |
| US3056836A (en) | Aralkylamines and methods of preparation thereof | |
| DE2167044C2 (de) | E-homo-eburnanderivate | |
| AU2017209925B2 (en) | Aryl substituted pyrimidines for use in influenza virus infection | |
| CN105143203A (zh) | 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物 | |
| PT77331B (en) | Process for the separation of a racemic mixture of aryl- or he teroaryl-oxypropanolamines beta-adrenergics | |
| PH14332A (en) | 4-hydroxyphenylalkanolamine derivatives | |
| US4252825A (en) | Compositions for treatment of cardiovascular conditions associated with overproduction of catecholamines | |
| US20160102074A1 (en) | Substituted amide compounds | |
| EP1951673B1 (de) | Heterocyclische cetp-hemmer | |
| MX9304070A (es) | Piperidilamidas, piperidilsulfonamidas y piperidilsulfoxamidas novedosas como inhibidores de la biosintesis del colesterol. | |
| DE2322699C2 (de) | Quecksilberfreie Diuretika | |
| AU2013304942A1 (en) | Extended release compositions of an aminoalkyl nitrate | |
| ATE547394T1 (de) | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen | |
| WO2016135263A1 (en) | No donors for the treatment of stress-induced pulmonary haemorrhage in animals |